These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15075086)

  • 1. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.
    Martinelli G; Rondoni M; Buonamici S; Ottaviani E; Piccaluga PP; Malagola M; Baccarani M
    Haematologica; 2004 Apr; 89(4):495-7. PubMed ID: 15075086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely.
    Martinelli G; Buonamici S; Visani G; Malagola M; Piccaluga PP; Isidori A; Bosi C; Bonifazi F; Soverini S; Terragna C; Amabile M; Giannini B; Baccarani M
    Leukemia; 2003 Mar; 17(3):650-1; author reply 651-2. PubMed ID: 12646962
    [No Abstract]   [Full Text] [Related]  

  • 4. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
    Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
    Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
    Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
    Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
    Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
    Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Malagola M; Piccaluga P; Baccarani M
    Haematologica; 2002 May; 87(5):554-5. PubMed ID: 12010674
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
    Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
    Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
    Marcucci G; Caligiuri MA; Döhner H; Archer KJ; Schlenk RF; Döhner K; Maghraby EA; Bloomfield CD
    Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
    Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
    Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of CBF beta-MYH11 fusion transcript and inv(16)(p13;q22) in acute myelomonocytic leukemia(M4) by RT-PCR and FISH].
    He K; Gu B; Cao Q
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):23-6. PubMed ID: 10921098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
    Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
    Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study.
    Mitterbauer M; Laczika K; Novak M; Mitterbauer G; Hilgarth B; Pirc-Danoewinata H; Schwarzinger I; Haas OA; Fonatsch C; Lechner K; Jaeger U
    Am J Clin Pathol; 2000 Mar; 113(3):406-10. PubMed ID: 10705822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature.
    Fujieda A; Nishii K; Tamaru T; Otsuki S; Kobayashi K; Monma F; Ohishi K; Nakase K; Katayama N; Shiku H
    Leuk Res; 2006 Aug; 30(8):1053-7. PubMed ID: 16504290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.